These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 33667843)

  • 1. Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy.
    Gaston TE; Ampah SB; Martina Bebin E; Grayson LP; Cutter GR; Hernando K; Szaflarski JP;
    Epilepsy Behav; 2021 Apr; 117():107862. PubMed ID: 33667843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study.
    Szaflarski JP; Bebin EM; Cutter G; DeWolfe J; Dure LS; Gaston TE; Kankirawatana P; Liu Y; Singh R; Standaert DG; Thomas AE; Ver Hoef LW;
    Epilepsy Behav; 2018 Oct; 87():131-136. PubMed ID: 30100226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of cannabidiol (CBD) in children with treatment-resistant epilepsy: Results from a state-based expanded access program.
    Park YD; Linder DF; Pope J; Flamini JR; Moretz K; Diamond MP; Long SA
    Epilepsy Behav; 2020 Nov; 112():107474. PubMed ID: 33181893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsy.
    Gaston TE; Szaflarski M; Hansen B; Bebin EM; Szaflarski JP;
    Epilepsy Behav; 2019 Jun; 95():10-17. PubMed ID: 31003195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
    Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
    Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US.
    Sands TT; Rahdari S; Oldham MS; Caminha Nunes E; Tilton N; Cilio MR
    CNS Drugs; 2019 Jan; 33(1):47-60. PubMed ID: 30460546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results.
    Szaflarski JP; Bebin EM; Comi AM; Patel AD; Joshi C; Checketts D; Beal JC; Laux LC; De Boer LM; Wong MH; Lopez M; Devinsky O; Lyons PD; Zentil PP; Wechsler R;
    Epilepsia; 2018 Aug; 59(8):1540-1548. PubMed ID: 29998598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol.
    Szaflarski JP; Hernando K; Bebin EM; Gaston TE; Grayson LE; Ampah SB; Moreadith R
    Epilepsy Behav; 2019 Jun; 95():131-136. PubMed ID: 31048098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsy.
    Martin RC; Gaston TE; Thompson M; Ampah SB; Cutter G; Bebin EM; Szaflarski JP
    Epilepsy Behav; 2019 Aug; 97():105-110. PubMed ID: 31220785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabidiol normalizes resting-state functional connectivity in treatment-resistant epilepsy.
    Nenert R; Allendorfer JB; Bebin EM; Gaston TE; Grayson LE; Houston JT; Szaflarski JP
    Epilepsy Behav; 2020 Nov; 112():107297. PubMed ID: 32745959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program.
    Gaston TE; Bebin EM; Cutter GR; Ampah SB; Liu Y; Grayson LP; Szaflarski JP;
    Epilepsy Behav; 2019 Sep; 98(Pt A):201-206. PubMed ID: 31382177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-term efficacy of cannabidiol in the treatment of refractory epilepsy.
    Patel S; Grinspoon R; Fleming B; Skirvin LA; Wade C; Wolper E; Bruno PL; Thiele EA
    Epilepsia; 2021 Jul; 62(7):1594-1603. PubMed ID: 34050682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam.
    Savage TE; Sourbron J; Bruno PL; Skirvin LA; Wolper ES; Anagnos CJ; Thiele EA
    Epilepsy Res; 2020 Feb; 160():106263. PubMed ID: 31923763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy.
    Pietrafusa N; Ferretti A; Trivisano M; de Palma L; Calabrese C; Carfì Pavia G; Tondo I; Cappelletti S; Vigevano F; Specchio N
    Paediatr Drugs; 2019 Aug; 21(4):283-290. PubMed ID: 31179531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: Four-year results from the expanded access program.
    Szaflarski JP; Devinsky O; Lopez M; Park YD; Zentil PP; Patel AD; Thiele EA; Wechsler RT; Checketts D; Sahebkar F
    Epilepsia; 2023 Mar; 64(3):619-629. PubMed ID: 36537757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
    Devinsky O; Marsh E; Friedman D; Thiele E; Laux L; Sullivan J; Miller I; Flamini R; Wilfong A; Filloux F; Wong M; Tilton N; Bruno P; Bluvstein J; Hedlund J; Kamens R; Maclean J; Nangia S; Singhal NS; Wilson CA; Patel A; Cilio MR
    Lancet Neurol; 2016 Mar; 15(3):270-8. PubMed ID: 26724101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex.
    Hess EJ; Moody KA; Geffrey AL; Pollack SF; Skirvin LA; Bruno PL; Paolini JL; Thiele EA
    Epilepsia; 2016 Oct; 57(10):1617-1624. PubMed ID: 27696387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy.
    Villanueva V; García-Ron A; Smeyers P; Arias E; Soto V; García-Peñas JJ; González-Alguacil E; Sayas D; Serrano-Castro P; Garces M; Hampel K; Tomás M; Lara J; de Toledo M; Barceló I; Aledo-Serrano A; Gil-Nagel A; Iacampo L; Falip M; Saiz-Diaz RA; Gómez-Ibañez A; Sopelana D; Sanchez-Larsen A; López-González FJ
    Epilepsy Behav; 2022 Dec; 137(Pt A):108958. PubMed ID: 36327646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjunctive Transdermal Cannabidiol for Adults With Focal Epilepsy: A Randomized Clinical Trial.
    O'Brien TJ; Berkovic SF; French JA; Messenheimer JA; Sebree TB; Bonn-Miller MO; Gutterman DL;
    JAMA Netw Open; 2022 Jul; 5(7):e2220189. PubMed ID: 35802375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.